Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease
Authors:
- Louise S. DalbøgeLDLouise S. Dalbøge
- Michael ChristensenMCMichael Christensen
- Martin Rønn MadsenMMMartin Rønn Madsen
- Thomas SecherTSThomas Secher
- Nicole EndlichNENicole Endlich
- Vedran Drenic’VDVedran Drenic’
- Alba Manresa-ArrautAMAlba Manresa-Arraut
- Henrik H. HansenHHHenrik H. Hansen
- Ida RuneIRIda Rune
- Lisbeth N. FinkLFLisbeth N. Fink
- Mette V. ØstergaardMØMette V. Østergaard
Open Access
- 11 July 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1661
Abstract
Background: Obesity, hyperglycemia and hypertension are critical risk factors for development of diabetic kidney disease (DKD). Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP-1R) agonists improve cardiovascular and renal outcomes in type 2 diabetes patients. Here, we characterized the effect of the long-acting GLP-1R agonist semaglutide alone and in combination with an ACE inhibitor (lisinopril) in a model of hypertension-accelerated, advanced DKD facilitated by adeno-associated virus-mediated renin overexpression (ReninAAV) in uninephrectomized (UNx) female diabetic db/db mice. Methods: Female db/db mice received a single intravenous injection of ReninAAV 1 week prior to UNx. Six weeks post-nephrectomy, db/db UNx-ReninAAV mice were administered (q.d.) vehicle, semaglutide (30 nmol/kg, s.c.) or semaglutide (30 nmol/kg, s.c.) + lisinopril (30 mg/kg, p.o.) for 11 weeks. Endpoints included blood pressure, plasma/urine biochemistry, kidney histopathology and RNA sequencing. Results: Vehicle-dosed db/db UNx-ReninAAV mice developed hallmarks of DKD characterized by severe albuminuria and advanced glomerulosclerosis. Semaglutide robustly reduced hyperglycemia, hypertension and albuminuria concurrent with notable improvements in glomerulosclerosis severity, podocyte filtration slit density, urine/renal kidney injury molecule-1 (KIM-1) levels and gene expression markers of inflammation and fibrogenesis in db/db UNx-ReninAAV mice. Co-administration of lisinopril further ameliorated hypertension and glomerulosclerosis. Conclusions: Semaglutide improves disease hallmarks in the db/db UNx-ReninAAV mouse model of advanced DKD. Further benefits on renal outcomes were obtained by adjunctive antihypertensive standard of care. Collectively, our study supports the development of semaglutide for management of DKD.Keywords
This publication has 65 references indexed in Scilit:
- Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosisJournal of Clinical Investigation, 2013
- The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutideNeuropharmacology, 2012
- Exendin-4 has an anti-hypertensive effect in salt-sensitive mice modelBiochemical and Biophysical Research Communications, 2009
- Proteinuria: is it all in the foot?Journal of Clinical Investigation, 2007
- Glomerulosclerosis and Tubulointerstitial Fibrosis are Attenuated with 17β-Estradiol in the Aging Dahl Salt Sensitive RatJournal of the American Society of Nephrology, 2004
- Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patientsNephrology Dialysis Transplantation, 2004
- Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive ratsJournal Of Hypertension, 2003
- Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibitionJournal of Cellular Physiology, 2003
- Pathophysiology of proteinuriaKidney International, 2003
- Obstructive Uropathy and Hydronephrosis in Male KK-Ay Mice: A Report of Cases.Journal of Veterinary Medical Science, 1999